UNSPSC 51421907: Naflocort anhydrous

This classification denotes a therapeutic glucocorticoid with the molecular formula C29H33FO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1V2C47TW7H, chemically known as 2'h-naphtho(2',3':16,17)pregna-1,4-diene-3,20-dione, 9-fluoro-1',4'-dihydro-11,21-dihydroxy-, (11.beta.,16.beta.)-, but more generally known as naflocort anhydrous, which bears US NIH Compound Identifier 64767.

European Medicines Agency schedules naflocort anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09124MIG. Most nations, for tariff purposes, schedule naflocort anhydrous under HS 29372200. SMILES: C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(CC5CCCCC5C4)C(=O)CO)CCC6=CC(=O)C=C[C@@]63C)F)O.

UNSPSC 51421907 Naflocort anhydrous is a Commodity code that in recent state and local procurement activity covers pharmaceutical products and related health-system supplies procured to support community health and pharmacy benefit initiatives. State and local issuing bodies soliciting under this code include county health departments and state health and human services agencies. The scope of work reflects actual pharmaceutical procurement: Seminole County, Florida recently solicited naloxone and drug deactivation systems for community health delivery, while the Texas Health and Human Services Commission issued a Request for Information exploring direct-to-manufacturer prescription fulfillment models to improve pharmacy benefit program efficiency and cost management. Both initiatives represent public-sector pharmaceutical acquisition supporting health outcomes and operational efficiency rather than narrow pharmaceutical manufacturing or research applications.

Recent activity is concentrated in Florida and Texas. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the bid deadline was July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, with a response deadline of April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. Both opportunities reflect public health priorities—opioid response and prescription cost management—that drive recurring demand in this code space. Vendors responding to these procurements must meet standard state and local compliance requirements including drug-free workplace certification, E-Verify enrollment, and appropriate insurance coverage.